politics
2025 Trump Tariffs on Pharmaceutical Imports
Trump announces soon-to-be tariffs on pharmaceutical imports, we dig into how much Novo Nordisk and Eli Lilly could be affected.
company:novo-nordisk
category:news
Hims pivots to branded Tirzepatide, generic Liraglutide
Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.
research
STRIDE study: GLP1s vs peripheral artery disease (PAD)
Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
category:news
Novo Nordisk licenses GLP1 drug from United BioTechnology, a Chinese research firm
Novo Nordisk licenses the right to sell a new GLP1 being developed in China -- 15% weight loss in 12 weeks (in an admittedly small study).
company:novo-nordisk
Novo Nordisk offers cheaper Wegovy
Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
category:watercooler
Shortages threaten corporate profits, likely to end soon
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:news
Ozempic approved for Chronic Kidney Disease
The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
company:novo-nordisk
Novo's Amycretin delivers great Phase 2 results
Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.
government
Government Price negotiations on Ozempic and Wegovy
The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
category:howto
What's the best injection site for GLP1s?
What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.
drug:amycretin
Novo's new GLP1: Amycretin
Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.
chemical:semaglutide
24% Less kidney disease risk with Semaglutide (Ozempic)
Can we trust research funded by Novo Nordisk which found a 24% decrease in kidney disease risk for people on Semaglutide (Ozempic)?